20-Deoxy-20-fluorocamptothecin: Design and synthesis of camptothecin isostere

Synlett

Volumn , Issue 14, 2004, Pages 2509-2512

  Shibata, Norio ^a   Ishimaru, Takehisa ^a   Nakamura, Mai ^a   Toru, Takeshi ^a  

^a NAGOYA INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

Antitumor agent; Asymmetric synthesis; Camptothecin; Fluorine; Topoisomerase I

Indexed keywords

20 DEOXY 20 FLUOROCAMPTOTHECIN; 20 DEOXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; BENZENE DERIVATIVE; CAMPTOTHECIN DERIVATIVE; CINCHONA ALKALOID; DNA TOPOISOMERASE; FLUORINE DERIVATIVE; LACTONE DERIVATIVE; N FLUOROBENZENESULFONIMIDE; NATURAL PRODUCT; SULFONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ADDITION REACTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASYMMETRIC SYNTHESIS; CHIRALITY; CIRCULAR DICHROISM; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOMER; ENANTIOSELECTIVITY; FLUORINATION; HYDROGEN BOND; MOLECULAR INTERACTION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; REDUCTION; REPRODUCIBILITY; RING OPENING; STEREOCHEMISTRY; STRUCTURE ANALYSIS; SUBSTITUTION REACTION; TECHNIQUE; X RAY CRYSTALLOGRAPHY;

EID: 9644302441     PISSN: 09365214     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-834810     Document Type: Article

References (51)

1. (a) Wall, M. E.; Wani, M. C.; Cook, C. E.; Palmer, K. H.; McPhail, A. T.; Sim, G. A. J. Am. Chem. Soc. 1966, 88, 3888.
2. (b) Wall, M. E. Med. Res. Rev. 1998, 18, 299.
3. For a review of the camptothecin biochemistry see: Liehr, J.; Giovanella, B. C.; Verschraegen, C. F. Ann. N. Y. Acad. Sci. 2000, 922, 1.
4. (a) Craig, J. T.; Nicholas, J. R.; Sidney, M. H. Bioorg. Med. Chem. 2004, 12, 1585.
5. (b) Redinbo, R. R.; Stewart, L.; Kuhn, P.; Champoux, J. J.; Hol, W. G. J. Science 1998, 279, 1504.
6. (a) Wall, M. E.; Wani, M. C.; Nicholas, A. W.; Manikumar, G.; Tele, C.; Moore, L.; Truesdale, A.; Leitner, P.; Besterman, J. M. J. Med. Chem. 1993, 36, 2689.
7. (b) Wang, X.; Zhou, X.; Hecht, S. M. Biochemistry 1999, 38, 4374.
8. (a) Jaxel, C.; Kohn, K. W.; Wani, M. C.; Wall, M. E. Cancer Res. 1989, 49, 1465.
9. (b) Fassberg, J.; Stella, V. J. J. Pharm. Sci. 1992, 81, 676.
10. (a) Hertzberg, R. P.; Caranfa, M. J.; Holden, K. G.; Jakas, D. R.; Gallagher, G.; Mattern, M. R.; Mong, S. M.; Bartus, J. O.; Johnson, R. K.; Kingsbury, W. D. J. Med. Chem. 1989, 32, 715.
11. (b) Zhao, H.; Lee, C.; Sai, P.; Choe, Y. H.; Boro, M.; Pendri, A.; Guan, S.; Greenwald, R. B. J. Org. Chem. 2000, 65, 4601.
12. (a) Biomedical Aspects of Fluorine Chemistry; Filler, R.; Kobayashi, Y., Eds.; Kodansha/Elsevier Biomedical: Tokyo, 1982.
13. (b) Biomedical Frontiers of Fluorine Chemistry, ACS Symposium Series 639; Ojima, I.; McCarthy, J. R.; Welch, J. T., Eds.; American Chemical Society: Washington DC, 1996.
14. (c) Fusso Yakugaku; Kobayashi, Y.; Kumadaki, I.; Taguchi, T., Eds.; Hirokawa: Tokyo, 1992.
15. (d) Welch, J. T. Tetrahedron 1987, 43, 3123.
16. (e) Smart, B. E. In Organofluorine Chemistry: Principles and Commercial Applications; Banks, R. E.; Smart, B. E.; Tatlow, J. C., Eds.; Plenum: New York, 1994, Chap. 3, 57.
17. (a) Shibata, N.; Tarui, T.; Doi, Y.; Kirk, K. L. Angew. Chem. Int. Ed. 2001, 40, 4461.
18. (b)Takeuchi, Y.; Tarui, T.; Shibata, N. Org. Lett. 2000, 2, 639.
19. (c) Takeuchi, Y.; Shiragami, T.; Kimura, K.; Suzuki, E.; Shibata, N. Org. Lett. 1999, 1, 1571.
20. (d) Shibata, N.; Das, B. K.; Takeuchi, Y. J. Chem. Soc., Perkin Trans. 1 2000, 4234.
21. (e) Takeuchi, Y.; Kirihara, K.; Kirk, K. L.; Shibata, N. Chem. Commun. 2000, 785.
22. (f) Shibata, N.; Das, B. K.; Honjo, H.; Takeuchi, Y. J. Chem. Soc., Perkin Trans. 1 2001, 1605.
23. (g) Das, B. K.; Shibata, N.; Takeuchi, Y. J. Chem. Soc., Perkin Trans. 1 2002, 197.
24. The ability of the C-F bond to act as a hydrogen bond acceptor is a matter of considerable debate. It highly depends on the molecular structures. See: Shibata, N.; Das, B. K.; Harada, K.; Takeuchi, Y.; Bando, M. Synlett 2001, 1755; and references therein.
25. (a) Nicholas, A. W.; Wani, M. W.; Manikumar, G.; Wall, M. E.; Kohn, K. W.; Pommier, Y. J. Med. Chem. 1990, 33, 972.
26. (b) Ejima, A.; Terasawa, H.; Sugimori, M.; Ohsuki, S.; Matsumoto, K.; Kawato, Y.; Yasuoka, M.; Tagawa, H. Chem. Pharm. Bull. 1992, 40, 683.
27. Adamovics, J. A.; Cina, J. A.; Hutchinson, C. R. Photochemistry 1979, 18, 1085.
28. (a) Muniz, K. Angew. Chem. Int. Ed. 2001, 40, 1653.
29. (b) Hintermann L., Togni A.; Angew. Chem. Int. Ed.; 2000, 39, 4359.
30. (c) Piana, S.; Devillers, I.; Togni, A.; Rothlisberger, U. Angew. Chem. Int. Ed. 2002, 41, 979.
31. (d) Togni, A.; Mezzetti, A.; Barthazy, P.; Becker, C.; Devillers, I.; Frantz, R.; Hintermann, L.; Perseghini, M.; Sanna, M. Chimia 2000, 55, 801.
32. (e) Cahard, D.; Audouard, C.; Plaquevent, J.-C.; Roques, N. Org. Lett. 2000, 2, 3699.
33. (f) Mohar, B.; Baudoux, J.; Plaquevent, J.-C.; Cahard, D. Angew. Chem. Int. Ed. 2001, 40, 4214.
34. (g) Kim, D. Y.; Park, E. J. Org. Lett. 2002, 4, 545.
35. (h) Hamashima, Y.; Yagi, K.; Takano, H.; Tamas, L.; Sodeoka, M. J. Am. Chem. Soc. 2002, 124, 14530.
36. (i) Ma, J.-A.; Cahard, D. Tetrahedron: Asymmetry 2004, 15, 1007.
37. (j) Ibrahim, H.; Togni, A. Chem. Commun. 2004, 1147.
38. (a) Shibata, N.; Suzuki, E.; Takeuchi, Y. J. Am. Chem. Soc. 2000, 122, 10728.
39. (b) Shibata, N.; Suzuki, E.; Asahi, T.; Shiro, M. J. Am. Chem. Soc. 2001, 123, 7001.
40. (c) Shibata, N.; Ishimaru, T.; Suzuki, E.; Kirk, K. L. J. Org. Chem. 2003, 68, 2494.
41. (d) Shibata, N. Pharmacia 2003, 39, 666.
42. Shibata, N.; Ishimaru, T.; Nagai, T.; Kohno, J.; Toni, T. Synlett 2004, 1703.
43. -1 (λ/nm) -0.06 (402.0), -1.88 (360.8), 0 (309.3), +0.32 (304.2), 0 (291.3), -0.08 (288.8), 0 (284.5), +18.2 (232.8),+6.10 (221.0).
44. (a) Lin, L.; Shen, J.; Zhou, T.; Shen, C.; Ke, M. Huaxue Xuebao 1989, 47 (5), 506.
45. (b) Kitajima, M.; Nakamaura, M.; Takayama, H.; Saito, K.; Stockigt, J.; Amii, N. Tetrahedron Lett. 1997, 38, 8997.
46. (a) Jennings, J. P.; Klyne, W.; Scopes, P. M. J. Chem. Soc. 1965, 7211.
47. (b) Lowe, G.; Potter, B. V. L. J. Chem. Soc., Perkin Trans. 1 1980, 2029.
48. (c) Kirk, D. N. Tetrahedron 1986, 42, 777.
49. (d) Takeuchi, Y.; Suzuki, T.; Satoh, A.; Shiragami, T.; Shibata, N. J. Org. Chem. 1999, 64, 5708.
50. Mazzinia, S.; Belluccia, M. C.; Dallavallea, S.; Fraternalib, F.; Mondelli, R. Org. Biomol. Chem. 2004, 2 (4), 505.
51. In initial cytotoxicity study, both 20(S)- and 20(R)-fluoroCPT (2) were evaluated on three human cancer cell lines (KB, A549 and HT-29) and they appeared to be less active than CPT (1). Further biological study using pure enantiomer of 2 is now under considerations.